| Cat. No. |
Product Name |
Information |
| PC-20708 |
HSN608
RET inhibitor
|
HSN608 (HSN 608) is a potent inhibitor of RET solvent-front mutants, inhibits RET G810 solvent-front mutants and the V804M gatekeeper mutant with IC50 of <50 nM in cell culture, inhibits ABL1(T315I) with IC50 of 40.7 nM. |
| PC-49616 |
RET agonist BT18
RET agonist
|
RET agonist BT18 is a small molecule allosteric agonist (ligand) of GDNF family receptor GFRα1 and RET receptor tyrosine kinase RetA function. |
| PC-49375 |
TPX-0046 enantiomer
RET inhibitor
|
TPX-0046 (Enbezotinib) enantiomer is a potent, selective next-generation RET/SRC inhibitor, demonstrates low nanomolar potency against WT and 18 RET mutations/fusions, as well as SRC, and is VEGFR2/KDR-sparing. |
| PC-38426 |
Vepafestinib
RET inhibitor
|
Vepafestinib (TAS0953, HM06) is a next-generation RET inhibitor, potently inhibits recombinant WT RET kinase with IC50 of 0.33 nM, targets RET wild-type (WT) kinase and RET solvent front mutants (RETL730, RETV804 and RETG810). |
| PC-73416 |
TPX-0046
RET inhibitor
|
TPX-0046 (Enbezotinib) is a potent, selective next-generation RET/SRC inhibitor, demonstrates low nanomolar potency against WT and 18 RET mutations/fusions, as well as SRC, and is VEGFR2/KDR-sparing. |
| PC-72475 |
BOS172738
RET inhibitor
|
BOS172738 (Zeteletinib, DS 5010) is a potent, selective oral RET kinase inhibitor with nanomolar potency against wtRET and RET mutations (Ki <1 nM), >300-fold selectivity against VEGFR2. |
| PC-72323 |
SYHA1815
RET inhibitor
|
SYHA1815 (SYHA-1815) is a novel potent, selective RET inhibitor, inhibits the kinase activity of RET wild type (IC50=0.9 nM) and V804 mutant (IC50=3.1 nM). |
| PC-72010 |
RET agonist BT44
RET agonist
|
RET agonist BT44 is a novel, specific RET agonist, promotes RET phosphorylation and selectively activates downstream cascades in the cells expressing GFL receptors. |
| PC-35286 |
GSK3179106
RET inhibitor
|
GSK3179106 (GSK-3179106, GSK 3179106) is a potent, selective, first-in-class and gut-restricted RET kinase inhibitor with IC50 of 0.4 and 11 nM in the biochemical assay and cellular assay respectively, 273-fold selectivity over KDR. |
| PC-35268 |
AD80
RET inhibitor
|
AD80 is a multikinase inhibitor that shows strong activity against human RET (IC50=4 nM), BRAF, S6K, and SRC, but has greatly reduced mTOR activity. |
| PC-63475 |
BLU-667
RET inhibitor
|
BLU-667 (Pralsetinib, BLU667) is a highly potent, selective, next generation RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. |
| PC-62829 |
RET-IN-23c
RET inhibitor
|
RET-IN-23c is a potent and selective RET kinase inhibitor with IC50 of 61.2 nM, shows no significant inhibitory effect against VEGFR-2 and KDR. |
